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Abstract 
 
 
 
GENETIC VARIATIONS OF CYP2B6 ENZYME AND THE RESPONSE TO 
MEPERIDINE IN ORAL SEDATION 
by Heath Austin Whitfield D.D.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of 
Science in Dentistry at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2010 
 
Major Director: Tegwyn H. Brickhouse D.D.S., Ph.D 
Associate Professor, Department of Pediatric Dentistry 
 
 
 
Purpose: The purpose of this study was to determine the relationship of the 
CYP2B6 genotype to the clinical response to meperidine in pediatric dental patients. 
Methods: Forty-nine patients, ASA I/ II, 41–101 months old, received an oral 
sedative regimen containing meperidine for dental treatment. The North Carolina Behavior 
Rating Scale (NCBRS) and Overall Effectiveness of Sedation Scale (OESS) were used to 
assess their behavior and sedation outcome. Saliva DNA samples were genotyped by PCR-
RFLP.   
  
   
Results: We found the following genotype distributions: homozygous wild-type 
1*1 (n = 19, 39%), heterozygous 1*6 (n = 25, 51%), and homozygous variant 6*6 (n = 5, 
10%). The genotypes showed a significant difference in the North Carolina Behavior 
Rating Scores and a trend towards significance of the Overall Effectiveness of Sedation 
Scale during meperidine oral sedations.   
Conclusion: This research concludes that variations of the CYP2B6 enzyme can be 
used in the prediction of successful behaviors for oral sedations that include meperidine in 
the drug regimen. Future research regarding the enzyme kinetics of meperidine is needed 
to determine the exact enzymatic function of CYP2B6 and its variants. 
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INTRODUCTION 
 
 According to the American Academy of Pediatric Dentistry (AAPD) moderate 
sedation (formerly known as conscious sedation or sedation/analgesia) is defined as 
“drug-induced depression of consciousness during which patients respond purposefully to 
verbal commands…either alone or accompanied by light tactile stimulation” 1. In 1996, a 
survey by Wilson et al of 1758 AAPD members found that 40% of members use sedation 
1 to 5 times per week and 20% use sedation more than 5 times per week.2  It is estimated 
that more than 1 million children have been sedated by pediatric dentists since 1985.2 
Meperidine (Demerol®) is commonly used for moderate sedation in pediatric 
dentistry. Meperidine’s popularity in pediatric sedation is due to its fast on-set of 
approximately 15 minutes following oral administration. Peak sedation is achieved in 
approximately 2 hours and subsides over several hours. 3, 4 Meperidine is an opioid 
analgesic that was originally developed as an anticholinergic drug.5, 6 It acts on the mu 
() receptors found in the central nervous system (CNS) and on the neural elements in the 
bowel.3, 7 Its opioid analgesic properties include inducing sedation, reducing reaction to 
painful stimuli and reducing motor activity.3 Meperidine’s side effects include 
hypotension, histamine release, nausea and vomiting, and decreased sensitivity to CO2 
leading to respiratory depression.4, 7 Meperidine is primarily metabolized in the human 
liver by N-demethylation to form the active metabolite normeperidine (6-N-
desmethylmeperidine), which is a potent stimulant of the CNS with no analgesic 
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properties.7, 8 The accumulation of normeperidine can cause neurotoxicity and produce 
symptoms such as delirium, nervousness, tremor, muscle twitches and seizures.7, 8 
Adverse drug reactions (ADRs) are a problem. Annually in the United States just 
over 2 million ADRs are estimated to occur, with approximately 100,000 resulting in 
death.9 Meperidine may contribute to this problem is some patients. A review of pediatric 
dental adverse events and their contributing factors from 1969 through March 20, 1996 
by Cote et al. found 95 reported incidents: 51 resulted in death, 9 in permanent 
neurologic injury, 21 in prolonged hospital stay without injury and 14 experienced no 
harm.10 Twenty-nine of the 60 incidents resulting in death and permanent neurologic 
injury were related to various specialties in dentistry. 10  
In 2001, Leelataweedwud et al. examined 195 cases of conscious sedation in 
pediatric dentistry with the classic triple cocktail of chloral hydrate, meperidine and 
hydroxyzine.11 The study found a success rate of 72%, while 23% were unsuccessful and 
5% were aborted.11 There were 3% with adverse events reported which included 
vomiting, desaturation, prolonged sedation and apneic episodes.11 The incidence of 
meperidine ADRs is consistent with genetic variation being a partial causative factor. 
Reducing ADRs is especially important when administering drugs to children in 
an outpatient setting. Outpatient procedures requiring children to receive sedation include 
gastrointestinal procedures, MRI scans, dental rehabilitation, and procedures completed 
in the emergency department. The most commonly used opioid analgesics for moderate 
sedation and analgesia are fentanyl and meperidine.12 Common adverse effects of these 
drugs, when used as single agents can include over-sedation, respiratory depression, 
mental clouding, delirium, seizures, hypotension, flushing, sweating and pruritis. While 
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not lethal, these effects are common with and without significant co-morbidities. 
Practitioners today are unable to predict, without error, who will and who will not have 
an adverse drug reaction. Using pharmacogenomics to select medications could 
potentially increase therapeutic responsiveness from the 50% it is today to almost 75%, 
while dramatically reducing the number of ADRs occurring each year.13 
Pharmacogenetics could revolutionize pediatric sedation, and lead to increased patient 
satisfaction and safety. 
The cytochrome P450 monooxygenase enzyme group is a multigene family of 
hepatic enzymes that are responsible for the oxidative metabolism of most medicines. 
Genetic variation in the metabolic activity of these enzymes can have a negative effect on 
drug efficacy and safety. Genetic polymorphisms in these and other enzymes can be used 
to guide drug treatment. Figure 1 shows the following isoenzymes which are responsible 
for the in vitro metabolism of the meperidine: CYP2B6, CYP3A4, and CYP2C19, with 
CYP2B6 being the major enzyme that metabolizes meperidine.14 In addition its action in 
the liver, CYP2B6 has also been identified in the human brain.15, 16  
The CYP2B6 gene is located on chromosome 19, between 19q12 and 19q13.2 and 
is composed of 9 exons.17, 18, 19 Haplotype analysis demonstrates the presence of multiple 
alleles including the most common form or wild-type CYP2B6*1, and the most common 
variant, CYP2B6*6.20 The activity of CYP2B6 varies between individuals and this 
variation has been shown to be genetic.14 The diagnostic variant in the haplotype 
CYP2B6*6, is a single nucleotide polymorphism of G to T in exon 4 that results in a 
substitution of Gln to His at amino acid 172 (516G>T, Gln172His). 21 This change is 
associated with a significant loss of function as measured by enzymatic activity.21 This 
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variation is clinically relevant. For example, the CYP2B6*6 variant has been reported to 
affect the pharmacokinetics of efavirenz (EFV), a first line medication for treatment of 
human immunodeficiency virus (HIV) patients.20, 21 Patients who are homozygous 
CYP2B6*6 experience more adverse neurological events such as fatigue and mood 
disorders when they are put on long term EFV therapy compared to those who are 
homozygous wild type.21 
  In pediatric dentistry, we often encounter children who are unable to tolerate 
dental procedures comfortably despite traditional behavior management techniques and 
adequate local anesthesia. These children require sedation in order to receive care.1 This 
group of patients, because of their age, is considered more susceptible to the adverse 
effects of sedatives and narcotics on the respiratory drive, loss of protective airway 
reflexes and airway obstruction.1 Currently, oral sedative agent selection is based on the 
patient’s behavior, weight, medical history, physical exam and anticipated duration of the 
dental procedures. Structured sedation protocols have shown to reduce morbidities and 
enhanced sedation safety for pediatric patients.1 However there remains an element of 
unpredictability of response to sedation. One source of variability is thought to be 
genetics.  
It is unknown at this time what affects the CYP2B6*6 allele may have on the 
pharmacokinetics of meperidine. It may be associated with either an increase or decrease 
in enzymatic activity, which may have varying clinical effects such as slower drug 
clearance, resulting in prolonged sedation, or at the other end of the range excitability. 
The specific aim of this study is to determine the relationship between the CYP2B6 
genotype at this one loci and behavioral responses to meperidine in pediatric dental 
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patients. A secondary aim was to examine physiological parameters during the oral 
sedation according to genotype.
 6
 
  METHOD AND MATERIALS 
 
Sample and data collection  
Forty-nine patients previously identified as requiring oral sedation for dental treatment 
were recruited to participate in our research from the VCU School of Dentistry Pediatric Dental 
Clinic. Patient ages ranged from 41 to 101 months at the time of treatment. All patients were 
ASA I or II. The patients received an oral sedative regimen containing meperidine combined 
with one or more of the following medicines: chloral hydrate, hydroxyzine (Vistaril®) and 
midazolam (Versed®).  
Informed consent for dental treatment under oral sedation, physical restraint and 
participation in the study were obtained from the parent/guardian. An assent form was obtained 
from patients who were 7 years or older for the saliva collection for CYP2B6 genetic testing. 
Saliva has been shown to be a viable and noninvasive method for obtaining DNA for genetic 
analysis.22  
Prior to the administration of oral sedation medications baseline vital signs were 
obtained. After administration of the medications by the treating dental resident, the patients and 
their parents/guardian remained in the pre-op room for at least 30 minutes before the start of the 
dental procedure. Once in the treatment room, a blood pressure cuff and precordial stethoscope 
were applied and the patient was placed on a papoose board. Treatment began once all of the 
monitoring equipment was in place and the patient was comfortable. The patient’s heart rate, 
blood pressure, and oxyhemoglobin saturation rate (SaO2) were recorded at five minute intervals. 
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Respiratory status and breath sounds were monitored throughout the procedure via the precordial 
stethoscope by the treating pediatric dental resident.  
The behavior of the child during the treatment was recorded using the North Carolina 
Behavior Rating Scale (NCBRS) and the overall effectiveness of the sedation was rated using the 
Overall Effectiveness of Sedation Scale (OESS).23, 24   Vital signs, physiological parameters and 
behavior scores were charted by a monitoring provider. Once the AAPD discharge criteria1 were 
met the parents/guardian were escorted into the treatment room to meet the patient. Post-
operative instructions were given in verbal and written formats to the patients and their 
parents/guardian.  
Adverse events were defined as follows: desaturation was when the pulse oximeter, SaO2, 
reading was below 95%; apnea was when there was no breath sounds via precordial stethoscope 
and no visible sign of chest rise for greater than 25 seconds; excessive sedation was when the 
patient required more than 30 minutes to recover; seizure, nausea and vomiting.  
Data collection was standardized prior to the start of this research. All nine residents and 
full-time faculty at the VCU Pediatric Dental Department were trained and calibrated by 
assessing 10 videotaped sedations that were not part of this study. The calibration videos were of 
patients of record at VCU Pediatric Dental Department who needed sedation for dental 
treatment. Informed consents for videotaping, physical restraint with a papoose board and 
standard treatment during oral sedation were obtained from the parent/guardian. The calibration 
training entailed watching the videos of 10 taped sedations and assessing each patient’s behavior 
based on the North Carolina Behavior Rating Scale (NCBRS) during critical events at every 5 
minute intervals (see Appendix 1). The Overall Effectiveness of Sedation Scale (OESS) was used 
to rate the overall success of the oral sedation appointment ranging from “successful to 
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unsuccessful” depending on how the patient’s behavior affected the treatment outcome (see 
Appendix 1). The calibration study indicated significant agreement (Kappa = 0.60, p < .0001).25 
 
Genetic analysis 
For each patient, 2 ml of saliva was collected using Oragen DNA (OG-300) self DNA 
collection kit before and after the treatment. The patient’s saliva was collected and the genetic 
analysis of CYP2B6 was done at a later date.  
The DNA was extracted manually from 2ml of un-induced saliva by using QIAamp DNA 
Blood Mini Kit (Valencia, CA, USA), following the manufacturer’s instructions. PCR amplified 
the exonic *6 variable region of CYP2B6.21  
The genotyping analysis was done with restriction fragment length polymorphism 
(RFLP). To generate the CYP2B6 526bp product, the following primers were used: 2B6*6F 5' - 
GGT CTG CCC ATC TAT AAA C - 3' and 2B6*6R 5' - CTG ATT CTT CAC ATG TCT GCG - 
3'. The PCR product was digested with Fermentas BseNI restriction endonuclease enzyme. The 
digestion of the CYP2B6*6 variant allele 516TT amplicons yielded two fragments of 23 and 503 
bp and that of the CYP2B6*1 wild type allele 516GG amplicons resulted in 3 fragments of 23, 
236 and 267 bp. The digestion products were separated on a 2% agrose gel using electrophoresis, 
and banding patterns were visualized under UV light then photo documented.  
 
Statistical Analyses 
To compare the observed genotype frequencies with those expected under Hardy-
Weinberg equilibrium, a chi-square test with one degree of freedom was used. The primary aim 
was to test the association between CYP2B6 genotypes (homozygous for the normal allele = 
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1*1, heterozygous = 1*6, and homozygous for the variant allele = 6*6) and clinical response 
(behavior and sedation effectiveness), using data from the North Carolina Behavior Rating Scale 
and the Overall Effectiveness of Sedation Scale.  
The groups were compared using a chi-square analysis for nominal outcomes and 
analysis of variance (ANOVA) for continuous outcomes. Multivariable analyses were 
accomplished using a repeated-measures mixed-model ANOVA (SAS software. JMP8.0 or 
SAS9.2, Cary NC). The study was approved by the Virginia Commonwealth University 
Institutional Review Board Committee on Investigations Involving Human Subjects. Clinical 
data was collected in the VCU Pediatric Dental Clinic and the DNA isolation was performed at 
the VCU School of Pharmacy in the laboratory of Dr. Bukaveckas and PGXL Laboratories 
(Louisville, KY, USA).  
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RESULTS 
 
Preliminary analyses 
The demographic characteristics of the patients (n = 49) are shown in Table 1. The 
patients were primarily African Americans (n = 32), with 12 Caucasians, 1 Asian and 4 were 
marked of other race. There were 28 females and 21 males. The patient’s ages ranged from 41 
months to 101 months with an average age of 63.1 months at time of treatment. The majority of 
subjects (80%) were ASA I status, while the rest were ASA II. The mean time of treatment 
duration was 24.8 minutes with a range of 5 minutes to 63 minutes. The patients were 
categorized into three genotypes and identified as: 1*1 for homogenous wild-type allele CYP2B6 
(n = 19, 39%), 6*6 for homogenous variant allele (n = 5, 10%), and 1*6 for heterozygous allele 
(n = 25, 51%). These proportions were different than the expected values (25%, 50%, 25%, chi-
square = 8.02, df = 2, p =0.0181) under the Hardy-Weinberg equilibrium. Comparing the 
demographic characteristics in Table 1, there were no significant differences between the 
genotypes (ps > 0.09). 
 The medications used in the patients are described in Table 2. The three drug 
combination of meperidine, midazolam, hydroxyzine was used in 57% of the cases. The second 
most common drug regimen was meperidine, vistiril, and chloral hydrate, used in 31% of the 
cases. The meperidine and midazolam combination was used three times and the meperidine and 
hydroxyzine combination was used once. In one case, Propofol® was used by converting to an 
intravenous sedation (IVS) due to failed oral sedation.  
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 In the study cohort (n=49), 49% received restorations (n = 24), 19% extractions (n = 9), 
20% both restorations and extractions (n = 10), and in 12% of the cases the planned procedures 
were not performed and the process was aborted (n = 6). There were no instances of apnea or 
nausea, two instances of vomiting, three instances of desaturation and three instances of excess 
sedation meaning the patients too longer than 30 minutes post-op for recovery. 
 
Primary analyses 
 The primary goal of the study was to compare the North Carolina Behavior Rating Scale 
Scores and Overall Effectiveness of Sedation Scores between three genotype groups: 
CYP2B6*1*1, CYP2B6*1*6 and CYP2B6*6*6 during oral sedation. The NCBRS was recorded 
on 363 occasions (between 0 and 14 times per patient) and had a mean = 1.87, SD = 1.06. 
NCBRS was not assessed during the post-operative period.  Table 3 shows the Analysis of 
NCBRS during the oral sedations. The results of the repeated-measures ANOVA indicated that 
NCBRS did vary across event types (p < 0.0001), that the genotypes did not differ (p = 0.0897) 
within themselves and that the event differences did not vary within the genotype (p > 0.2, see 
Table 4).  However, within the Intraoperative measures, the three genotypes were significantly 
different (p = 0.0221). Specifically, the 1*1 homozygous wild type’s intraoperative behavior was 
significantly different than the 6*6 homozygous variant’s (p = 0.0061) (see Table 3 and Figure 
2).  
Table 4 shows the number of individuals in each genotype and sedation effectiveness 
combination. The genotype groups did not show a statistically significant difference in the 
overall effectiveness (Wilcoxon rank-sum chi-square = 5.68, df = 2, p = 0.0585), but a strong 
trend towards significance. The overall effectiveness of sedation score may be high for some 
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patients. If the patient was extremely vocal during the procedure, the treating dentist may have 
rated the overall sedation in a more negative manner despite the fact the child remained still and 
treatment proceeded without complications. However, as may be seen in the table 4, the 
CYP2B6*1*1 genotype had the most effective success scores (median effectiveness = 2) while 
the homozygous variant, CYP2B6*6 genotype had the worst (median = 4).   
 A stepwise regression analysis of the demographic characteristics and drug regimens was 
performed to determine if the difference between genotypes could also be explained by a 
confounding factor. Only Versed (p = 0.0878), Chloral Hydrate (p = 0.0140) and Propofol (p = 
0.0088) emerged as potential confounders (using an alpha cut-off of 0.2). There is some 
indication of a race difference (p = 0.0741). Including these in the model did not change the 
conclusion that overall effectiveness scores did not differ by genotype (p = 0.2980). 
 
 
Secondary analyses 
 
The secondary analysis focused on outcomes that were assessed on repeated occasions 
during the course of each child’s procedure. These outcomes were: HR, Dia-BP, Sys-BP, and 
SaO2. Each of these outcomes were analyzed separately with a repeated-measures ANOVA with 
the following factors in the model: Event type (Baseline, preOp, IntraOp, and PostOp), genotype 
(the three values), and an event*genotype interaction.  
 The heart rate, (HR) was recorded on 581 occasions (between 2 and 19 times per patient) 
and had a mean = 100.4, SD = 19.9. The results of the repeated-measures ANOVA indicated that 
HR did vary across event types (p < .0001), that the genotypes did not differ (p > 0.4) and that 
the event differences did not vary within genotype (p > 0.4, see Table 6). The estimated mean 
heart rate for each event is also shown in Table 6 and Figure 3. Tukey’s HSD indicated that the 
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PreOp mean was not significantly different than any of the others and that each of the others was 
significantly different from one another. 
 The systolic blood pressure (Sys-BP) was recorded on 555 occasions (between 2 and 18 
times per patient) and had a mean = 119.7, SD = 19.3. The results of the repeated-measures 
ANOVA indicated that Sys-BP did vary across event types (p = .0014), that the genotypes did 
not differ (p > 0.7) and that the event differences did not vary within genotype (p > 0.5, see 
Table 7). The estimated mean systolic BP for each event is also shown in Table 7 and Figure 4. 
Tukey’s HSD indicated that only the IntraOp value was significantly higher than PreOp and 
Baseline. 
 The diastolic blood pressure (Dia-BP) was recorded on 555 occasions (between 2 and 18 
times per patient) and had a mean = 67.0, SD = 12.8. The results of the repeated-measures 
ANOVA indicated that Dia-BP did vary across event types (p = .0034), that the genotypes did 
not differ (p > 0.9) but the event differences did vary with genotype (p = 0.0275, see Table 5). 
The estimated mean dia-BP for each event is also shown in Table 8 and Figure 5. Overall, 
Tukey’s HSD indicated that the PostOp values were higher than Baseline or PreOp and other 
differences were not significant. But, the significant interaction indicates that this pattern may be 
different depending upon the genotype. Specifically, there is no difference between the event 
types within the 1*1 genotype group (p > 0.5). 
 The oxygen saturation, SaO2, was recorded on 577 occasions (between 2 and 19 times per 
patient) and had a mean = 98.7, SD = 1.4. Since SaO2 was so strongly skewed, with 90% of the 
values above 98, this outcome was analyzed on the log-scale and then the summary results back 
transformed to the original scale. The results of the repeated-measures ANOVA indicated that 
SaO2 did vary across event types (p > 0.0497), that the genotypes did not differ (p > 0.8) and that 
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the event differences did not vary within genotype (p > .9, see Table 9). The estimated mean 
SaO2 for each event is also shown in Table 9 and Figure 6. There were three cases where patients 
experienced desaturation (<95% SaO2). 
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DISCUSSION 
 
Genetic findings: 
 In vitro studies of CYP2B6 have shown that all variant alleles encode functionally active 
proteins.26, 27 The mean protein expression level of those who were heterozygous, 1*6, compared 
to that of the wild type, 1*1, did not show a significant reduction (Lang et al 2000). However, 
there was a reduction of approximately 50% in protein expression for those who were 
homozygous 6*6.26 This was as expected from a clinical efavirenz (EFV) study where they 
found that homozygous for the *6 variant allele had more than three-fold higher plasma drug 
concentration than those who were wild types.21 In a study by Rodriguez-Novoa et al. 40% 
homozygous 6*6 and 19% of heterozygous had EFV concentration >4g/mL, which is the toxic 
level. Nearly 20% of homozygous 1*1 and 2% of homozygous 6*6 showed sub therapeutic level 
of EVF of <1g/mL.28 The clinical relevance to their research was the individuals who carried 
the wild type allele had sub therapeutic concentration of EFV and were at risk for treatment 
failure; in contrast, those who were homozygous 6*6 experienced neurological adverse effects 
more frequently. As expected, a reduction in enzymatic function was more likely to lead to an 
accumulation of EFV plasma concentration within the toxic range. 
The homozygous variant CYP2B6*6, homozygous wild-type CYP2B6*1, and 
heterozygous CYP2B6 genotypes were present in 10%, 39% and 51% of our population, 
respectively. There were no statistical significant differences found between the demographic 
characteristics and the genotypes (ps > 0.09).  
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Behavioral Findings 
Interestingly, our study results showed the opposite of what was expected based on in 
vitro studies of CYP2B6 function.  There was a statistical significant difference in NCBRS 
scores and genotypes during the intraoperative phases of oral sedation (p = 0.0221) (see Table 3). 
Specifically, the homozygous wild-type CYP2B6*1 was significantly different than the 
homozygous variant CYP2B6*6 as can be seen by observing the 95% CI (p = 0.0061) (see Table 
3 and Figure 2).  The CYP2B6*1 showed significantly more favorable NCBRS scores than the 
CYP2B6?*6 during the intraoperative treatment intervals. This finding is of significant 
importance to practitioners in that the success of sedation often depends on behavior at the time 
of dental treatment or intraoperative phase. 
 There was not a statistical significance in OESS outcome, (chi-square = 5.68, df = 2, p = 
0.0585) between the genotypes, but a strong trend towards significance. Table 4 showed that the 
homozygous wild-type, 1*1, had a median OESS of 2, which translated to a moderately 
successful sedation with moderate amount of crying and movement. In patients who were 
homozygotes for 6*6, they had a median score of 4 which was interpreted as an unsuccessful 
sedation outcome, with continuous crying and movements throughout sedation, treatment 
performed with difficulty, and treatment progression was hindered.   
One possible explanation to the phenotypes observed in our study was the possibility of 
one amino acid substitution of Gln172His mutation caused by natural single-nucleotide 
polymorphism enhancing the enzymatic activity of CYP2B6*6. Ariyoshi et al in vitro enzyme 
kinetic study demonstrated that wild-type CYP2B6*1 followed the classical hyperbolic 
Michaelis-Menten kinetics while the variant allele CYP2B6*6 showed the sigmoidal kinetics 
with a higher Vmax value compared to that of the wild-type enzyme.29 Sigmoidal kinetics plot 
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indicates cooperative binding of substrate to the active site which means that the binding of one 
substrate molecule affects the binding of subsequent substrate molecules. Allosteric activation by 
its substrate, also called homotropic cooperativity, is also seen in CYP3A4 mediated drugs 
metabolism.29 This auto activation phenomenon appears dependent on the substrate.29 
CYP2B6*6 catalytic activity may be enhanced with meperidine. This would explain the 
phenotypes observed in our study population. The patients who were homozygous 6*6 may have 
metabolized meperidine at a faster rate, leading to accumulation of normeperidine, which is 
associated with symptoms of neurotoxicity and CNS excitation. Furthermore, blood levels of 
normeperidine: meperidine AUC ratio is higher when it is delivered orally compared to the 
parenteral route.30, 31, 32 While delirium, tremor, muscle twitches and seizures did not occur in the 
study, the NCBRS for 4 patients with the variant allele were classified as “wild” meaning defiant 
with undesirable behaviors (crying, screaming, head movement, torso movement, hand 
movement or foot movement at critical events). Such phenotypes can be interpreted as symptoms 
of CNS stimulation by normeperidine. One patient with the variant allele had an NCBRS and 
OESS of 1.  This patient differed from the other 6*6 patients in that Chloral hydrate was used in 
the drug regimen.  
It appears that CYP2B6 and its variants activity may be generally predictable by genetic 
diagnosis and is dependent upon their substrate. Our research showed that future investigations 
will be needed to exactly determine the enzyme CYP2B6*6 properties toward meperidine. 
Future studies involve CYP2B6 variants and meperidine pharmacokinetics may help to explain 
whether there is an increase in normeperidine concentration in plasma and in peripheral blood 
mononuclear cells due to enhanced enzymatic activity caused by auto activation.  
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Physiologic findings 
In the study population (n=49), 12% were aborted due to the patient’s behaviors. Adverse 
events were reported as followed: 3 cases of excessive sedation (>30 minutes for recovery), 2 
case of vomiting, and 3 cases of desaturation. There were no instances of apnea or nausea.  In 
pediatric patients, nausea does not always precede vomit, which could occur instantaneously 
without warning. 
 In oral sedation, pediatric dental patients often cry and struggle during treatment 
therefore it is not uncommon to see “false alarms” meaning oxygen desaturation associated with 
movements. These “false alarms” should not be overlooked. In oral sedation, desaturation, when 
the pulse oximeter reading is <95%, could happen due to many reasons including hypoxia, 
hypoventilation, excessive patient movements that cause mechanical interference, or pressure 
that the operator exerts on the mandible creating a mechanical airway obstruction. In our study, 
the desaturation was found in three cases which was promptly adjusted back to normal readings 
of >95% SaO2 saturation after adjusting the position of the mandible and the pulse oximeter 
monitor. 
Vital signs (heart rate, BP, and SaO2) were not statistically significant between the 
different genotypes. The tendency for heart rate and systolic blood pressure to increase with 
different event types, such as baseline to intraoperative phase, was seen. Such a finding can be 
explained as during intraoperative phase, which was when the patient was stimulated with local 
anesthetic injection, rubber dam placement and dental operative procedures, the heart rate could 
increase. Of critical importance was the average heart rate, 105.83 beats/minute during the oral 
sedation fell within the normal range for children age 3 – 5, which is 80-125 beats/minute. In 
addition, the average systolic pressure was 121.18 during the intraoperative phase, which is on 
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the high end of normal limits of systolic pressure for children age 3 – 5, which is 108-121 
mmHg. 
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CONCLUSION 
 
 
Many studies have focused on parameters maximizing sedation success while minimizing 
ADRs associated with oral sedation medicines. However, at this time, no studies have looked 
into the genetic component to oral sedation medicine, specifically meperidine, and the sedation 
outcomes. Our research allows for the conclusion that variations of the CYP2B6 enzyme could 
predict for successful behavior in oral sedations using meperidine. While meperidine, at the 
recommended dosage, is considered safe for oral sedation, the usefulness of CYP2B6 genetic 
analysis to personalize medicine may increase patient safety and satisfaction.  
Genotyping patients for the variant allele CYP2B6*6 prior to receiving meperidine as an 
oral sedative for dental treatment in young children may prove to be important for identifying 
individuals with genetic predisposition for sedation failure, unnecessary anesthesia risks, 
economical, physical and emotional distress for both the child and the parent. Further research 
investigating CYP2B6 and its variants exact enzymatic function with respect to meperidine will 
contribute to the clinical significance of this enzyme. 
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Table 1: Demographic Characteristics 
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2 24
8
2
4
5 92
2
8 57
43
9 80
0 20
Characteristic n %
Race
AA 32 65
Asian 1 2
C 1
O 4
Ethnicity
B 1
H 2
N 4
Y 1
Gender
F 2
M 21
ASA (1,2)
1 3
2 1
Wt (kg)
Mean 22.0
SD 5.5
Min. 15
Max 38
Duration of tx (min)
Mean 24.8
SD 13.5
Min. 5
Max 63
Age
Mean 4.8
SD 1.1
Min. 3
Max 8
Age (months)
Mean 63.1
SD 12.9
Min. 41
Max 101  
 
 Table 2: Medications 
Medications n %
Drug regime
Dem Vis Ver 28 57
Dem Vis CH 15 31
Dem Ver 3 6
Dem Vis 1 2
Dem Vis Ver CH Pro 1 2
Dem Vis Ver Pro 1 2
Local
none 8 16
L+epi 19 39
L+epi Sept 3 6
Sept 19 39
N2O use
N2O 42 86
none 7 14  
Abbreviations: Dem = Demerol, Vis = Vistaril, Ver = Versed, CH = Chloral hydrate, Pro = 
Propofol, L = Lidocaine, Sept = Septocaine, N2O = Nitrous oxide. 
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Table 3: Analysis of NCBRS 
Source df Num. df Den. F p-value
Event 2 308.9 18.42 <.0001
Genotype 2 52.99 2.524 0.0897
Event*Genotype 4 308.3 1.343 0.2540
Event LS Mean
Genotype 1*1
Baseline 1.47 1.00 1.95
PreOp 1.49 1.02 1.96
IntraOp 1.91 1.55 2.28
Genotype 1*6
Baseline 1.26 0.83 1.69
PreOp 1.44 1.02 1.87
IntraOp 2.20 1.87 2.52
Genotype 6*6
Baseline 2.00 1.07 2.93
PreOp 2.40 1.47 3.33
IntraOp 3.10 2.35 3.84
95% CI
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 Table 4: Comparing Overall Effectiveness 
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n1 2 3 4 Media
1*1 7 5 6 1 2
1*6 5 6 5 9 3
6*6 1 1 3 4
Overall EffectivenessCYP2B6 
genotype
 
 
 
 
 
  
 
 Table 5: Analysis of Heart Rate 
Source df Num. df Den. F p-value
Event 3 530.40 14.51 <.0001
Genotype 2 51.63 0.77 0.4686
Event*Genotype 6 529.80 1.11 0.3568
Event LS Mean SE
Baseline 89.70 3.49 82.80 96.61
PreOp 94.86 3.65 87.65 102.08
IntraOp 105.83 2.77 100.29 111.37
PostOp 100.84 2.79 95.25 106.43
95% CI
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Table 6: Analysis of Systolic Blood Pressure 
Source df Num. df Den. F p-value
Event 3 503.30 5.27 0.0014
Genotype 2 49.84 0.30 0.7448
Event*Genotype 6 502.80 0.82 0.5564
Event LS Mean SE
Baseline 113.61 3.75 106.20 121.03
PreOp 112.55 3.54 105.55 119.55
IntraOp 121.18 2.89 115.38 126.97
PostOp 117.78 2.93 111.91 123.65
95% CI
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Table 7: Analysis of Diastolic Blood Pressure 
Source df Num. df Den. F p-value
Event 3 508.20 4.62 0.0034
Genotype 2 55.48 0.04 0.9590
Event*Genotype 6 507.80 2.39 0.0275
Event LS Mean SE
Baseline 63.80 2.45 58.97 68.63
PreOp 63.21 2.27 58.72 67.69
IntraOp 68.05 1.67 64.70 71.39
PostOp 69.38 1.71 65.97 72.79
95% CI
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Table 8: Analysis of Oxygen Saturation 
Source df Num. df Den. F p-value
Event 3 530.40 2.63 0.0497
Genotype 2 56.68 0.19 0.8265
Event*Genotype 6 530.40 0.25 0.9599
Event LS Mean
Baseline 98.78 98.27 99.30
PreOp 98.46 97.93 99.00
IntraOp 98.49 98.14 98.85
PostOp 98.87 98.51 99.23
95% CI
 32
  
  
 
Figure 1. CYP450 isozymes responsible for meperidine metabolism. As illustrated in the figure, 
it has been demonstrated in vitro that Cytochrome P450, family 2, subfamily B, polypeptide 6 
(CYP2B6) is the enzyme primarily responsible for metabolism of meperidine 14 
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Figure 2: NCBRS 
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Figure 4: Systolic Blood Pressure 
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Figure 5: Diastolic Blood Pressure 
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APPENDIX A 
 
Behavior rating scales 
The North Carolina Behavior Rating Scale and Overall Effectiveness of Sedation Scale 
were used to assess clinical response to meperidine and compare the relationship of CYP2B6 
genotype and clinical response to meperidine. This appendix serves as a description of these 
scales. 
North Carolina Behavior Rating Scale (behavior): 
 The North Carolina Behavior Rating Scale (NCBRS) allows the practitioner and assistant 
to assess behavior at critical events of the procedure. Behavior ranging from quiet and 
cooperative (1) to wild and defiant (4) is scored at critical events.** 
1. Quiet: patient is quiet and/ or sleeping with only extraneous, inconsequential movements  
2. Annoyed: patient is cooperative for treatment, but with one or two of the undesirable 
behavior* 
3. Upset: patient is noticeably disturbed, with two to three undesirable behaviors* making 
treatment difficult but possible  
4. Wild: patient is extremely defiant with presence of all undesirable behaviors* making 
treatment extremely difficult.  
* An undesirable behavior includes crying, screaming, head movement, torso movement, hand or 
foot movements at critical events** 
** Critical events: local anesthetic delivery (L), rubber dam placement (R), operative phase (O) 
such as bur penetrating tooth to rubber dam removal and extraction, IV conversion (C).  
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Overall Effectiveness of Sedation Scale.  
1. Successful: Patient slept throughout procedure with only minimal crying/ movement at 
critical events* 
2. Moderately successful: Successful sedation with moderate amount of crying and movement 
but behavior did not hinder the progress of sedation 
3. Mildly successful: Treatment was accomplished as planned, but due to screaming/ combative 
movements throughout the sedation; the progression of portions of the treatment were 
hindered 
4. Unsuccessful: Continuous crying/movement throughout sedation; treatment was performed 
with difficulty; the progression of all treatment was hindered 
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